SCHEMBL6254565

SCHEMBL6254565

CCOP(=O)(OCC)C(CNc1ccc(C)nc1C)c1cc2ccc(OC)cc2s1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.37
CA2 P00918 2/20 0.33
NPC1 O15118 4/20 0.32
RAB9A P51151 4/20 0.32
MAPT P10636 4/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
MEN1 O00255 3/20 0.31
KMT2A Q03164 3/20 0.31
GAA P10253 3/20 0.31
LMNA P02545 1/20 0.31
POLB P06746 1/20 0.31
HPGD P15428 1/20 0.31
CHRNA7 P36544 2/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325868 0.90 HSD17B10 (0.32) HSD17B10CA2NPC1RAB9AMAPT
SCHEMBL6256850 0.89 CA2 (0.31) HSD17B10CA2MAPTPOLB
SCHEMBL6324062 0.87 CA2 (0.33) HSD17B10CA2NPC1RAB9AMAPT
SCHEMBL6256841 0.86 CA2 (0.33) HSD17B10CA2NPC1RAB9AMAPT
SCHEMBL6317265 0.85 CA2 (0.32) HSD17B10CA2NPC1RAB9AMAPT
SCHEMBL6308431 0.81 CA12 (0.40) HSD17B10CA2NPC1MAPTSMN1; SMN2
SCHEMBL6318976 0.75 CA2 (0.32) CA2CHRNA7
SCHEMBL6318633 0.74 MAPT (0.34) HSD17B10CA2NPC1RAB9AMAPT
SCHEMBL6314512 0.73 POLB (0.44) MAPTSMN1; SMN2KDM4EALDH1A1MEN1
SCHEMBL6306448 0.73 CA12 (0.38) CA2MAPTSMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143349-A1 Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels QUATRX PHARMACEUTICALS CO. 2005-06-30 US claimed
WO-2005058330-A1 PHOSPHORUS CONTAINING COMPOUNDS USEFUL FOR THE REGULATION OF LDL AND LP(A) LEVELS QUATRX PHARMACEUTICALS CO. (US) 2005-06-30 WO claimed
US-20050143349-A1 Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels QUATRX PHARMACEUTICALS CO. 2005-06-30 US disclosed
WO-2005058330-A1 PHOSPHORUS CONTAINING COMPOUNDS USEFUL FOR THE REGULATION OF LDL AND LP(A) LEVELS QUATRX PHARMACEUTICALS CO. (US) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143349-A1 Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels APOB, LDLR, LPL HSD17B10 2842/4885CA2 2047/4885NPC1 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.